Search The Web

Saturday, May 30, 2020

JAPANESE COMPANIES ACTIVE INTO BIOSIMILARS MANUFACTURING


  • Aska Pharmaceuticals - No major progress on the biobetter
  • Asahi Glass - Entering in Biopharma CDMO Business for Global Market
  • Chugai Pharmaceuticals - Entry to Authorised Biosimilar unlikely - Fighting for originator rights
  • Daiichi Sankyo - Potential to be a front runner in the biosimilar space with Amgen Partnership
  • Fuji Film Kyowa Kirin Biologics (FF-KKB) - Looking beyond domestic opportunities to capture global biosimilar business
  • Fuji Pharma - Alvotech partnership to bolster biosimilar business as its new core in the home ground
  • Gene Techno Science - JP Biopharma rising star - A reliable partner for Developing Biosimilar in Japan by Japanese Front End Companies
  • Itochu Chemical Frontier Corporation - A trading house with new role in biosimilar value chain
  • JCR Pharmaceuticals -A pioneer for biosimilars -now thrive in regenerative medicine & fast tracking NESP biosimilar
  • Kissei - Timely launch of NESP biosimilar - Next to watch! Focus to be a niche player in BS space
  • Kyowa Hakko Kirin - Tapping biosimilar market through Biosame launch -Taking advantage of front end leadership for Anemia and Heamatology therapy area
  • Meiji Seika Pharma (MSP) -Trastuzumab biosimilar launch awaited in Japan- Tough competition with already approved other players!
  • Mochida - Enbrel BS - first to file for Japan, now equipped with full basket for being one of the top biosimilar player in Japan
  • Mitsubishi Tanabe - Not in biosimilars area yet
  • MGC Pharma (now as Cultivec) - A Bio-pharmaceutical CMO - leveraging the findings gained through developing the mass-culture technology to develop biosimlars!
  • Nichi-Iko - Aspiring to capture overseas markets, committed to the biosimilar business in the US
  • Nipro Pharma - Not much development after Somatropin BS
  • Nippon Kayaku - Pioneering New Age' of biosimilars: After Remicade - now launch of Herceptin BS is key
  • Sawai - Intends to establish sales team in biosimilar field in next few years
  • Towa - Still waiting for Government right policy pitch for biosimilar
  • Toyobo Biologics - Eying at biosimilars CMO Business
  • Takeda Teva Pharmaceuticals - Noclarity on biosimilar launch plan in Japan
  • UMN Pharma - Transforming vaccines heritage into new generation biologics- but no major progress in last couple of years in biosimilar area
  • Yoshindo - A steady progress for Enbrel biosimilar- Three step approach to build a Bio Company
  • Sanwa Kagaku - NESP biosimilar - a therapy focus biosimilar entry for Japan market
  • Amgen - Timely launch is key through Daiichi Sankyo Partnership in Japan
  • Chong Kun Dang - With Fuji Pharma entering in NESP BS market

1 comment:

Hafeezriyas said...

Impressive! I really like this blog, keep update.
Thanks for giving this information…
ISO 22301 Certification Kuwait

Engageya